These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 8452352)
41. The pharmacokinetics of meropenem in volunteers. Bax RP; Bastain W; Featherstone A; Wilkinson DM; Hutchison M; Haworth SJ J Antimicrob Chemother; 1989 Sep; 24 Suppl A():311-20. PubMed ID: 2808215 [TBL] [Abstract][Full Text] [Related]
42. Pharmacokinetics of zileuton and its metabolites in patients with renal impairment. Awni WM; Wong S; Chu SY; Patterson K; Hansen R; Machinist JM; Drajesk J; Keane WF; Halstenson CE J Clin Pharmacol; 1997 May; 37(5):395-404. PubMed ID: 9156372 [TBL] [Abstract][Full Text] [Related]
43. Pharmacokinetics of famciclovir in subjects with varying degrees of renal impairment. Boike SC; Pue MA; Freed MI; Audet PR; Fairless A; Ilson BE; Zariffa N; Jorkasky DK Clin Pharmacol Ther; 1994 Apr; 55(4):418-26. PubMed ID: 8162668 [TBL] [Abstract][Full Text] [Related]
44. Plasma pharmacokinetics and urine concentrations of meropenem in ewes. Abo El Sooud K J Vet Pharmacol Ther; 2004 Feb; 27(1):27-30. PubMed ID: 14995963 [TBL] [Abstract][Full Text] [Related]
45. Pharmacokinetics of intravenous cefetamet and oral cefetamet pivoxil in patients with renal insufficiency. Kneer J; Tam YK; Blouin RA; Frey FJ; Keller E; Stathakis C; Luginbuehl B; Stoeckel K Antimicrob Agents Chemother; 1989 Nov; 33(11):1952-7. PubMed ID: 2610506 [TBL] [Abstract][Full Text] [Related]
46. Mezlocillin pharmacokinetics after single intravenous doses to patients with varying degrees of renal function. Frimodt-Möller N; Maigaard S; Toothaker RD; Bundtzen RW; Brodey MV; Craig WA; Welling PG; Madsen PO Antimicrob Agents Chemother; 1980 Apr; 17(4):599-607. PubMed ID: 6446877 [TBL] [Abstract][Full Text] [Related]
47. Pharmacokinetics of cidofovir in renal insufficiency and in continuous ambulatory peritoneal dialysis or high-flux hemodialysis. Brody SR; Humphreys MH; Gambertoglio JG; Schoenfeld P; Cundy KC; Aweeka FT Clin Pharmacol Ther; 1999 Jan; 65(1):21-8. PubMed ID: 9951427 [TBL] [Abstract][Full Text] [Related]
48. Pharmacokinetics and total elimination of meropenem and vancomycin in intensive care unit patients undergoing extended daily dialysis. Kielstein JT; Czock D; Schöpke T; Hafer C; Bode-Böger SM; Kuse E; Keller F; Fliser D Crit Care Med; 2006 Jan; 34(1):51-6. PubMed ID: 16374156 [TBL] [Abstract][Full Text] [Related]
49. Disposition of famotidine in renal insufficiency. Halstenson CE; Abraham PA; Opsahl JA; Chremos AN; Keane WF; Matzke GR J Clin Pharmacol; 1987 Oct; 27(10):782-7. PubMed ID: 3429684 [TBL] [Abstract][Full Text] [Related]
50. Pharmacokinetics of tofacitinib, a janus kinase inhibitor, in patients with impaired renal function and end-stage renal disease. Krishnaswami S; Chow V; Boy M; Wang C; Chan G J Clin Pharmacol; 2014 Jan; 54(1):46-52. PubMed ID: 24030917 [TBL] [Abstract][Full Text] [Related]
51. Comparison of the pharmacodynamics of meropenem in healthy volunteers following administration by intermittent infusion or bolus injection. Jaruratanasirikul S; Sriwiriyajan S J Antimicrob Chemother; 2003 Sep; 52(3):518-21. PubMed ID: 12917242 [TBL] [Abstract][Full Text] [Related]
52. Pharmacokinetics of ceftazidime in patients with renal insufficiency. Welage LS; Schultz RW; Schentag JJ Antimicrob Agents Chemother; 1984 Feb; 25(2):201-4. PubMed ID: 6370127 [TBL] [Abstract][Full Text] [Related]
53. Pharmacokinetics of fluconazole in renal failure. Berl T; Wilner KD; Gardner M; Hansen RA; Farmer B; Baris BA; Henrich WL J Am Soc Nephrol; 1995 Aug; 6(2):242-7. PubMed ID: 7579091 [TBL] [Abstract][Full Text] [Related]